BioSpace News Archive

Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) thanks Mr. Neim Malo, founder of Beefstro’s, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).

The University of Texas Medical Branch has been awarded a project agreement worth up to $87.4 million by the U.S. DOD’s JPEO-CBRND and the U.S. Department of HHS’ Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, through the Medical CBRN Defense Consortium Other Transaction Authority, for the development of a vaccine technology against advanced and emerging viral threats.

Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific Officer (CSO).

The global genotyping assay market size was USD 17.7 Billion in 2020 and is expected to register a robust CAGR of 22.4% during the forecast period.

The global advanced therapy medicinal products CDMO market size is expected to be worth around US$ 20.9 billion by 2030, according to a new report by Vision Research Reports.

Industry Luminary Brings Pharmaceutical and Financial Leadership to Team of Influential Experts Guiding BioAI Innovator’s Continued Growth

Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

Initiative to enable continuous oral vaccine and therapeutics manufacturing for diseases worldwide

TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer’s disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer’s.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.